RxDoctor Payments Data

Migdalia Molina, MD

Addiction Medicine · San Antonio, TXNPI 1538165162

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.6% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Lilly USA, LLC at 40.4% of the total. Reporting peaked in 2023 at $618 and has fallen 55.4% since, to $276 in 2025.

$1,751in general payments, 2019–2025

Across 95 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$708
  • Mannkind Corporation$211
  • Amgen$195
  • Viiv Healthcare Company$122
  • AbbVie$99
  • Dexcom, Inc.$94
  • plus $323 from 8 others

What the payments were for

  • Food & beverage$1,69197%
  • Gifts$593%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,751 in reported general payments places this provider in the 70th percentile of 42 addiction medicine providers in Texas.

See all addiction medicine providers in Texas

Medicare billing

Part B allowed, 2024
$12,911
Medicare patients
13
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin92$67,730
OzempicSemaglutide57$57,679
MounjaroTirzepatide55$57,559
TrulicityDulaglutide32$33,955
RybelsusSemaglutide27$30,380
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$18,592
FarxigaDapagliflozin Propanediol17$13,656
EliquisApixaban17$12,448
LinzessLinaclotide12$6,190
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$4,869
VascepaIcosapent Ethyl12$3,981
Tolterodine Tartrate ErTolterodine Tartrate13$3,186
Gabapentin93$917
Ezetimibe31$909
Pregabalin26$818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$708$91,51387 claims
Novo NordiskOzempic, Rybelsus$87$88,05984 claims
GSKTrelegy Ellipta$13$18,59226 claims
PfizerEliquis$24$12,44817 claims
AbbVieLinzess$99$6,19012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 42 addiction medicine providers in Texas.

Other addiction medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →